News | December 03, 2025
Citius Oncology's new therapy offers new hope for cutaneous T-cell lymphoma patients
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Presbyopia, the age-related loss of near vision, could soon be treated successfully
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
GV20 received an upfront payment and is eligible for additional milestone payments
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
The approval by the US FDA comes after extensive safety testing and manufacturing improvements
Subscribe To Our Newsletter & Stay Updated
